Literature DB >> 2261348

Measurement of fibrinogen binding to platelets in whole blood by flow cytometry: a micromethod for the detection of platelet activation.

T E Warkentin1, M J Powling, R M Hardisty.   

Abstract

Platelet fibrinogen binding in whole blood has been measured in vitro by flow cytometry using a commercially available, fluorescein isothiocyanate (FITC)-conjugated polyclonal antifibrinogen antibody. Fibrinogen-antifibrinogen immune complexes were formed in experimental conditions approaching antigen-antibody equivalence, but optimal reaction conditions in which their formation was prevented or minimized could be achieved. Immune complex formation was associated with fibrinogen binding to unstimulated platelets but did not significantly affect ADP-induced fibrinogen binding. Half-maximal fibrinogen binding occurred at about 0.4 microM ADP, and ADP-induced fibrinogen binding continued progressively during 20 min incubation with 10 microM ADP. Fibrinogen binding correlated closely with platelet glycoprotein IIb-IIIa expression in members of a family with Glanzmann's thrombasthenia, and, in double labelling experiments, with the binding of PAC1, a monoclonal antibody that binds to GP IIb-IIIa only after the exposure of fibrinogen receptors. These studies show that platelet fibrinogen binding can be reliably measured in whole blood by means of a polyclonal antifibrinogen antibody which does not discriminate between plasma and platelet-bound fibrinogen, despite the presence of an approximately 100-fold excess of the former.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2261348     DOI: 10.1111/j.1365-2141.1990.tb06373.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Aggregation efficiency of activated normal or fixed platelets in a simple shear field: effect of shear and fibrinogen occupancy.

Authors:  Z Xia; M M Frojmovic
Journal:  Biophys J       Date:  1994-06       Impact factor: 4.033

2.  Absence of platelet CD40L identifies patients with X-linked hyper IgM syndrome.

Authors:  D P Inwald; M J Peters; D Walshe; A Jones; E G Davies; N J Klein
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

Review 3.  Glanzmann's thrombasthenia: report of a case and review of the literature.

Authors:  Christopher Sebastiano; Michael Bromberg; Karen Breen; Matthew T Hurford
Journal:  Int J Clin Exp Pathol       Date:  2010-04-25

4.  Dynamics of platelet glycoprotein IIb-IIIa receptor expression and fibrinogen binding. I. Quantal activation of platelet subpopulations varies with adenosine diphosphate concentration.

Authors:  M M Frojmovic; R F Mooney; T Wong
Journal:  Biophys J       Date:  1994-11       Impact factor: 4.033

5.  A novel form of integrin dysfunction involving beta1, beta2, and beta3 integrins.

Authors:  Alison McDowall; David Inwald; Birgit Leitinger; Alison Jones; Ri Liesner; Nigel Klein; Nancy Hogg
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

6.  Quantitative detection of platelet GPIIb-IIIa receptor antagonist activity using a flow cytometric method.

Authors:  L J Green; P Marder; S L Um; J A Jakubowski; J B Lawrence
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

7.  A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition.

Authors:  Wei Mo; Yan-Ling Zhang; Hong-Shan Chen; Long-Sheng Wang; Hou-Yan Song
Journal:  J Thromb Thrombolysis       Date:  2008-11-09       Impact factor: 2.300

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.